Naturmega® Announces Peer-Reviewed Clinical Results for Ruby-O® Balance, Demonstrating Stronger Triglyceride Responder Outcomes with a Lower Omega-3 Dose
Naturmega, a pioneer in advanced lipid science, announced the results of its new clinical study evaluating Ruby-O® Balance, a next-generation omega-3 ingredient developed using its patented BPL-O3TM (Bonded Phospholipid Omega-3) molecular platform. The randomized, double-blind study, now peer-reviewed and published in BMC Complementary Medicine and Therapies, demonstrated clinically relevant triglyceride (TG) reductions and superior omega-3 efficiency in real-world, non-medicated adults with moderate hypertriglyceridemia, despite a lower daily dose compared to standard fish oil.
